M&A Deal Summary |
|
---|---|
Date | 2021-02-03 |
Target | GW |
Sector | Life Science |
Buyer(s) | Jazz Pharmaceuticals |
Deal Type | Add-on Acquisition |
Deal Value | 6.7B USD |
Advisor(s) | Goldman Sachs Centerview Partners (Financial) Cravath, Swaine & Moore Slaughter and May (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2003 |
Sector | Life Science |
Employees | 2,800 |
Revenue | 3.8B USD (2023) |
Jazz Pharmaceuticals is a specialty biopharmaceutical company that identifies, develops, and commercializes products to address unmet medical needs in focused therapeutic areas. Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland.
DEAL STATS | # |
---|---|
Overall | 6 of 6 |
Sector (Life Science) | 6 of 6 |
Type (Add-on Acquisition) | 6 of 6 |
Country (United Kingdom) | 1 of 1 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 6 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-08-12 |
Cavion
Charlottesville, Virginia, United States Cavion, Inc. is a clinical-stage biotechnology company. Cavion's portfolio of T-type calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures. Cavion, Inc. was founded in 2006 and is based in Charlottesville, Virginia. |
Buy | $313M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2022-03-28 |
Jazz Pharmaceuticals - Sunosi
Dublin, Ireland Jazz Pharmaceuticals' Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). |
Sell | $53M |